

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial	Comments
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Number Agreed	6	6	Date Agreed	30/11/2018	2	15/12/2018	2	Recruitment Finished	High number of screen failures.
15/SC/0448	183584	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the reduction of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and the clinical diagnosis of early diabetic kidney disease in addition to standard of care	Number Agreed	9	9	Date Agreed	24/03/2017	6	08/09/2018	10	Recruitment Finished	Target met.